Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies.

IF 3.5 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Current medicinal chemistry Pub Date : 2025-01-01 DOI:10.2174/0109298673341391241231054936
Ashish Sriram Mishra, Manimaran Vasanthan, Bhavna Ghosh, Ponnurengam Malliappan Sivakumar
{"title":"Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies.","authors":"Ashish Sriram Mishra, Manimaran Vasanthan, Bhavna Ghosh, Ponnurengam Malliappan Sivakumar","doi":"10.2174/0109298673341391241231054936","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer's disease (AD) remains a significant challenge in neurology, marked by progressive cognitive decline and neurodegeneration. Despite extensive research efforts, effective treatments are still lacking. Traditional drug discovery is often slow and costly, frequently resulting in limited success. Drug repurposing, which identifies new therapeutic uses for existing medications, has emerged as a promising approach to expedite AD treatment development. This review examines the potential of drug repurposing to transform AD therapy by utilizing the established safety profiles and known mechanisms of current drugs. We explore various repurposed drugs under investigation for AD, originally intended for cardiovascular, metabolic, and psychiatric conditions. Detailed discussions include how these drugs provide neuroprotective benefits by inhibiting amyloid-beta aggregation, reducing tau phosphorylation, and modulating neuroinflammation. Additionally, we emphasize the benefits of drug repurposing, such as shortened development timelines, lower costs, and increased chances of clinical success. By integrating current research findings, this review offers a thorough overview of the most promising repurposed drug candidates and their potential impact on AD treatment strategies. It stresses the importance of innovative approaches in AD research and calls for greater investment in drug repurposing initiatives. Through these strategies, we aim to accelerate the availability of effective treatments, providing renewed hope and a brighter future for those affected by this devastating disease.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":"6563-6602"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673341391241231054936","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Alzheimer's disease (AD) remains a significant challenge in neurology, marked by progressive cognitive decline and neurodegeneration. Despite extensive research efforts, effective treatments are still lacking. Traditional drug discovery is often slow and costly, frequently resulting in limited success. Drug repurposing, which identifies new therapeutic uses for existing medications, has emerged as a promising approach to expedite AD treatment development. This review examines the potential of drug repurposing to transform AD therapy by utilizing the established safety profiles and known mechanisms of current drugs. We explore various repurposed drugs under investigation for AD, originally intended for cardiovascular, metabolic, and psychiatric conditions. Detailed discussions include how these drugs provide neuroprotective benefits by inhibiting amyloid-beta aggregation, reducing tau phosphorylation, and modulating neuroinflammation. Additionally, we emphasize the benefits of drug repurposing, such as shortened development timelines, lower costs, and increased chances of clinical success. By integrating current research findings, this review offers a thorough overview of the most promising repurposed drug candidates and their potential impact on AD treatment strategies. It stresses the importance of innovative approaches in AD research and calls for greater investment in drug repurposing initiatives. Through these strategies, we aim to accelerate the availability of effective treatments, providing renewed hope and a brighter future for those affected by this devastating disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
改变阿尔茨海默病的治疗:揭示药物再利用策略的新潜力。
阿尔茨海默病(AD)仍然是神经病学的重大挑战,其特征是进行性认知能力下降和神经变性。尽管进行了广泛的研究,但仍然缺乏有效的治疗方法。传统药物的发现往往缓慢而昂贵,常常导致有限的成功。药物再利用,即确定现有药物的新治疗用途,已成为一种有希望加快阿尔茨海默病治疗发展的方法。这篇综述探讨了利用现有药物的既定安全性和已知机制来改变阿尔茨海默病治疗的药物再利用潜力。我们探索了各种正在研究的用于阿尔茨海默病的重新用途药物,最初用于心血管,代谢和精神疾病。详细讨论了这些药物如何通过抑制淀粉样蛋白聚集、减少tau磷酸化和调节神经炎症来提供神经保护作用。此外,我们强调药物再利用的好处,如缩短开发时间,降低成本,增加临床成功的机会。通过整合当前的研究成果,本综述全面概述了最有希望的候选药物及其对阿尔茨海默病治疗策略的潜在影响。它强调了在阿尔茨海默病研究中采用创新方法的重要性,并呼吁加大对药物再利用倡议的投资。通过这些战略,我们的目标是加快提供有效治疗,为受这一毁灭性疾病影响的人带来新的希望和更光明的未来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current medicinal chemistry
Current medicinal chemistry 医学-生化与分子生物学
CiteScore
8.60
自引率
2.40%
发文量
468
审稿时长
3 months
期刊介绍: Aims & Scope Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
期刊最新文献
Clinical Significance of HBOT in Hypoxia-Induced Pathophysiological Conditions: A Comprehensive Investigative Study. Non-Coding RNAs and Common Neurosurgical Conditions: A Key to Future Personalized Molecular Therapy. Poly Beta-Amino Esters Nanoparticles as a Promising Strategy for Colon Cancer Therapy: Covering Synthesis Mechanisms, Characterization, Preclinical and Clinical Progress, and Regulatory Challenges. Cold-Induced Gouty Arthritis: Exploring the Pathophysiological Link between Hyperuricemia and Gout Flare Triggers. Novel Indole Derivatives as SRC/EGFR Inhibitors: Synthesis, Biological Evaluation, and In Silico Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1